Drug-related pneumonitis induced by osimertinib as firstline treatment for EGFR-positive non-small cell lung cancer: A real-world setting

被引：0
|
作者：
Sato, Y. [1 ]
Sumikawa, H. [2 ]
Shibaki, R. [3 ]
Morimoto, T. [4 ]
Sakata, Y. [5 ]
Oya, Y. [6 ]
Tamiya, M. [7 ]
Suzuki, H. [8 ]
Matsumoto, H. [9 ]
Kijima, T. [10 ]
Hashimoto, K. [11 ]
Kobe, H. [12 ]
Hino, A. [13 ]
Inaba, M. [14 ]
Tsukita, Y. [15 ]
Ikeda, H. [16 ]
Arai, D. [17 ]
Maruyama, H. [18 ]
Sakata, S. [19 ]
Fujimoto, D. [3 ]
机构：
[1] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan
[2] Natl Hosp Org, Dept Radiol, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[3] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
[4] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan
[5] Saiseikai Kumamoto Hosp, Div Resp Med, Kumamoto, Japan
[6] Aichi Canc Ctr Hosp, Thorac Oncol, Nagoya, Aichi, Japan
[7] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan
[8] Osaka Prefectural Habikino Hosp, Dept Resp Med, Habikino, Japan
[9] Hyogo Kenritsu Amagasaki Hosp, Resp Med, Amagasaki, Hyogo, Japan
[10] Hyogo Coll Med, Resp Med & Hematol, Nishinomiya, Hyogo, Japan
[11] Toneyama Hosp, Dept Thorac Oncol, Natl Hosp Org, Toyonaka, Osaka, Japan
[12] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[13] Chiba Univ, Sch Med, Dept Respirol, Chiba, Japan
[14] Kumamoto City Hosp, Dept Resp Med, Kumamoto, Japan
[15] Tohoku Univ, Resp Med, Sendai, Miyagi, Japan
[16] Kimitsu Chuo Hosp, Dept Resp Med, Kisarazu, Japan
[17] Saiseikai Utsunomiya Hosp, Pulm Div, Dept Internal Med, Utsunomiya, Tochigi, Japan
[18] Kumamoto Rosai Hosp, Dept Resp Med, Yatsushiro, Japan
[19] Kumamoto Univ, Resp Med, Kumamoto, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1103P
引用
收藏
页码：S1055 / S1056
页数：2
相关论文
共 50 条
  • [1] Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer A Real-World Setting
    Sato, Yuki
    Sumikawa, Hiromitsu
    Shibaki, Ryota
    Morimoto, Takeshi
    Sakata, Yoshihiko
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Matsumoto, Hirotaka
    Yokoi, Takashi
    Hashimoto, Kazuki
    Kobe, Hiroshi
    Hino, Aoi
    Inaba, Megumi
    Tsukita, Yoko
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Sakata, Shinya
    Fujimoto, Daichi
    [J]. CHEST, 2022, 162 (05) : 1188 - 1198
  • [2] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    [J]. Investigational New Drugs, 2020, 38 : 1906 - 1914
  • [3] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
  • [4] A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
    Cortellini, Alessio
    Ficorella, Corrado
    Crisci, Roberto
    Divisi, Duilio
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6107 - 6111
  • [5] Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting
    Boyne, D. J.
    Jarada, T.
    Yusuf, A.
    O'Sullivan, D. E.
    Hu, L. X. Y.
    Brenner, D. R.
    Abbie, E.
    Rose, J. B.
    Eaton, K.
    Ewara, E. M.
    Cheung, W. Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S56 - S56
  • [6] Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study
    Kim, Taeyun
    Jang, Tae Won
    Choi, Chang Min
    Kim, Mi-Hyun
    Lee, Sung Yong
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Chan Kwon
    Lee, Sang Hoon
    Jang, Seung Hun
    Yoon, Seong Hoon
    Oh, Hyung-Joo
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1152 - 1170
  • [7] Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta
    Cheung, Winson Y.
    Carbonell, Chantelle
    Navani, Vishal
    Sangha, Randeep S.
    Ewara, Emmanuel M.
    Elia-Pacitti, Julia
    Iczkovitz, Sandra
    Jarada, Tamer N.
    Warkentin, Matthew T.
    [J]. CURRENT ONCOLOGY, 2024, 31 (08) : 4382 - 4396
  • [8] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [9] Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
    Dohm, A. E.
    Tang, J.
    Mills, M. N.
    Perez, B. A.
    Robinson, T. J.
    Creelan, B.
    Yu, H. H. M.
    Oliver, D. E.
    Ahmed, K. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E14 - E14
  • [10] The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion
    Kiritani, Ayu
    Amino, Yoshiaki
    Uchibori, Ken
    Akita, Takahiro
    Harutani, Yuhei
    Ogusu, Shinsuke
    Tsugitomi, Ryosuke
    Manabe, Ryo
    Ariyasu, Ryo
    Kitazono, Satoru
    Yanagitani, Noriko
    Nishio, Makoto
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S510 - S511
12345